Skip to content
ES
MARKETS / BALCAO / ESMC
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Escalon Medical Corp. ESMC

15 fiscal years on record · USD · FY2024 reported · SEC filings only
$12.0M
▲ 0.5% YoY
$105,525
$376,845
In brief

What this company does

The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices for ophthalmic applications. The Company distributes two intraocular gas products C3F8 and SF6, which are used by vitreoretinal surgeons as a temporary tamponade in detached retina surgery. The Company markets disposable surgical packs used in vitreoretinal surgery, including packs which aid surgeons in the process of injecting and extracting silicone oil. The Company assembles and distributes its ophthalmic surgical products at its 7,440 square foot leased facility in New Berlin, WI.

Written from the business description in Escalon Medical Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 29 September 2025. Every sentence was checked against that document before publication.

Growth
USD 12.0M
Revenue, FY2024 · full 15-year series below
Revenue $M Net income $M
FY2024 · Revenue 12.0 · Net income 0.1
10M20M-2M-4M20102012201420162018202020222024
Compound annual growth
+4.0%
+5.1%
−0.9%
+80.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +5.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
1 cents
of every revenue dollar became profit
Operating margin Net margin
FY2024 · Operating 1.1% · Net 0.9%
2%4%-5%-10%-15%20102012201420162018202020222024
ROE
FY2024 · ROE 5.7%
50%100%-50%-100%-150%20102012201420162018202020222024
Gross margin45.7%
Operating margin1.1%
Net margin0.9%
Return on assets2.2%
EBITDAUSD 171,036.00

Each USD of equity produced 6 cents of profit this year.

Cash & shareholders
—
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF 0.4
0.4M0.8M-0.8M-1.6M20102012201420162018202020222024
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 5.0M
EquityUSD 1.9M
CashUSD 545,835.00
Current ratio1.72×

Equity funds 38% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.0−0.00.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.0−0.00.0−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0·······0.00.00.0−0.0
Net income $B0.0−0.00.00.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.0−0.0−0.0
Free cash flow $B0.0−0.00.0−0.00.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.00−0.020.030.00−0.01−0.09−0.040.06−0.10−0.15−0.07−0.050.35−0.79−0.77
Dividend / sh $···············
Payout %···············
ROE %5.7−6.726.81.2−3.5−35.4−10.932.5−47.0−47.0−16.8−10.5117.3−174.0−93.0
Shares out B0.010.010.010.010.010.010.010.010.010.010.010.010.010.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 22 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inPennsylvania
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image